Immune Responses Regulated by Cannabidiol.
James M. Nichols,Barbara L. F. Kaplan +1 more
- 27 Feb 2020
- Vol. 5, Iss: 1, pp 12-31
229
TL;DR: Overall, the data overwhelmingly support the notion that CBD is immune suppressive and that the mechanisms involve direct suppression of activation of various immune cell types, induction of apoptosis, and promotion of regulatory cells, which, in turn, control other immune cell targets.
read more
Abstract: Introduction: Cannabidiol (CBD) as Epidiolex® (GW Pharmaceuticals) was recently approved by the U.S. Food and Drug Administration (FDA) to treat rare forms of epilepsy in patients 2 years of age and older. Together with the increased societal acceptance of recreational cannabis and CBD oil for putative medical use in many states, the exposure to CBD is increasing, even though all of its biological effects are not understood. Once such example is the ability of CBD to be anti-inflammatory and immune suppressive, so the purpose of this review is to summarize effects and mechanisms of CBD in the immune system. It includes a consideration of reports identifying receptors through which CBD acts, since the "CBD receptor," if a single one exists, has not been definitively identified for the myriad immune system effects. The review then provides a summary of in vivo and in vitro effects in the immune system, in autoimmune models, with a focus on experimental autoimmune encephalomyelitis, and ends with identification of knowledge gaps. Conclusion: Overall, the data overwhelmingly support the notion that CBD is immune suppressive and that the mechanisms involve direct suppression of activation of various immune cell types, induction of apoptosis, and promotion of regulatory cells, which, in turn, control other immune cell targets.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test.
Ila M. P. Linares,Antonio Waldo Zuardi,Antonio Waldo Zuardi,Luis C Pereira,Regina Helena Costa Queiroz,Raphael Mechoulam,Francisco S Guimarães,José Alexandre de Souza Crippa,José Alexandre de Souza Crippa +8 more
TL;DR: Findings confirm the anxiolytic-like properties of CBD and are consonant with results of animal studies describing bell-shaped dose-response curves, and Optimal therapeutic doses of CBD should be rigorously determined.
209
Cannabidiol: pharmacology and therapeutic targets
TL;DR: The molecular targets, pharmacokinetics, and safety and abuse liability of CBD are reviewed; additionally, the extant evidence on its potential therapeutic effects for neurological disorders, pain, inflammation, conditions related to immune function, psychiatric disorders, and substance use are described.
204
Industrial Hemp ( Cannabis sativa subsp. sativa ) as an Emerging Source for Value-Added Functional Food Ingredients and Nutraceuticals
TL;DR: This review aims to compile recent advances in the science of industrial hemp, with respect to its use as value-added functional food ingredients/nutraceuticals and health benefits, while also highlighting gaps in current knowledge and avenues of future research on this high-value multi-use plant for the global food chain.
194
A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
TL;DR: A narrative review of CBD's applications in human diseases: from mechanism of action to clinical trials.
165
Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Nilo Riva,Gabriele Mora,Gianni Sorarù,Christian Lunetta,Ottavia Eleonora Ferraro,Yuri Falzone,Letizia Leocani,Raffaella Fazio,Mauro Comola,Giancarlo Comi,Fabio Formaglio,Paolo Rossi,Marta Clerici,Yuri Matteo Falzone,Laura Pozzi,Daniele Martinelli,Federica Cerri,Ignazio Diego Lopez,Filippo Martinelli-Boneschi,Angelo Quattrini,Elisabetta Pieri,Kalliopi Marinou,Giorgia Querin,Valeria A. Sansone,Eleonora Maestri,Andrea Calvo,Adriano Chiò +26 more
TL;DR: In this proof-of-concept trial, nabiximols had a positive effect on spasticity symptoms in patients with motor neuron disease and had an acceptable safety and tolerability profile.
85
References
Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test.
TL;DR: The hypothesis that this cannabinoid has anxiolytic properties is reinforced, as CBD induced an anticonflict effect not mediated by benzodiazepine receptors or by non-specific drug interference on nociceptive threshold or water consumption.
204
Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial
Timna Naftali,Refael Mechulam,Amir Marii,Gila Gabay,Gila Gabay,Asaf Stein,Asaf Stein,Miriam Bronshtain,Miriam Bronshtain,Ido Laish,Ido Laish,Fabiana Benjaminov,Fabiana Benjaminov,Fred M. Konikoff,Fred M. Konikoff +14 more
TL;DR: In this study of moderately active Crohn’s disease, CBD was safe but had no beneficial effects, which could be due to the small dose of CBD, the small number of patients in the study, or the lack of the necessary synergism with other cannabinoids.
196
COX-2 and PPAR-γ Confer Cannabidiol-Induced Apoptosis of Human Lung Cancer Cells
Robert Ramer,Katharina Heinemann,J. Merkord,Helga Rohde,Achim Salamon,Michael Linnebacher,Burkhard Hinz +6 more
TL;DR: In lung cancer cell lines and primary cells from a patient with lung cancer, cannabidiol elicited decreased viability associated with apoptosis and caused upregulation of COX-2 and PPAR-γ in tumor tissue and tumor regression that was reversible by GW9662.
190
Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice
Ewa Kozela,Nirit Lev,Nathali Kaushansky,Raya Eilam,Neta Rimmerman,Rivka Levy,Avraham Ben-Nun,Ana Juknat,Zvi Vogel,Zvi Vogel +9 more
TL;DR: Phytocannabinoids like cannabidiol (CBD), devoid of psychoactive activity, are, potentially, safe and effective alternatives for alleviating neuroinflammation and neurodegeneration.
Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
Thomas Nadulski,Fritz Pragst,Gordon Weinberg,Patrik Roser,Martin Schnelle,Eva-Maria Fronk,Andreas M. Stadelmann +6 more
TL;DR: Evidence emerged from the total of the results that CBD partially inhibits the CYP 2C catalyzed hydroxylation of THC to 11-OH-THC.
182